文献速递血管炎

抗中性粒细胞胞质抗体相关血管炎的新治疗靶点

New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-Associated Vasculitis.
PubMed 文献 · Arthritis Rheumatol · 2021-02-03

抗中性粒细胞胞质抗体(ANCA)相关血管炎(AAV)是一种以小血管坏死性炎症和针对髓过氧化物酶或蛋白酶3的循环ANCA为特征的罕见系统性自身免疫病。当前重症治疗方案为高剂量糖皮质激素联合利妥昔单抗或环磷酰胺诱导缓解,继以持续低剂量治疗预防复发,但部分患者仍出现严重治疗相关副作用或复发。对AAV发病机制的新认识已识别出针对异常适应性自身免疫反应(B细胞和T细胞导向治疗)及固有免疫成分(补体、单核细胞和中性粒细胞)的新治疗靶点,预期这些新治疗单用或联用将带来更有效且毒性更低的方案。

要点

  • 当前重症AAV以高剂量糖皮质激素联合利妥昔单抗或环磷酰胺诱导缓解,继以持续低剂量治疗预防复发。
  • 部分患者仍出现严重治疗相关副作用或复发,需新治疗靶点解决这些问题。
  • 新靶点包括B细胞和T细胞导向治疗及针对补体、单核细胞和中性粒细胞等固有免疫成分的策略。

核心结论

  • 针对异常适应性自身免疫反应和固有免疫成分的新治疗靶点,有望为AAV患者带来更有效且毒性更低的治疗方案。

研究设计与样本

  • 本文为综述,基于对AAV发病机制新进展的总结,识别新治疗靶点,未报告系统检索范围。

主要发现

  • 当前重症AAV治疗方案可显著改善结局,但部分患者仍出现严重治疗相关副作用或复发。
  • 新治疗靶点包括针对B细胞和T细胞的适应性免疫导向治疗,以及针对补体、单核细胞和中性粒细胞的固有免疫导向策略。

临床怎么用

  • 在临床实践中,当前重症AAV仍以高剂量糖皮质激素联合利妥昔单抗或环磷酰胺诱导缓解,继以持续低剂量治疗预防复发。
  • 新治疗靶点单用或联用可能为减少治疗毒性和复发提供新选择,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a rare systemic autoimmune disease that is characterized by necrotizing inflammation of predominantly the small blood vessels and the presence of circulating ANCAs directed against myeloperoxidase or proteinase 3. Current treatment strategies for severe disease, supported by the findings of several well-coordinated randomized controlled trials, aim to induce remission with high-dose glucocorticoids and either rituximab or cyclophosphamide, followed by relapse prevention with a period of sustained low-dose treatment. This approach has dramatically improved outcomes in AAV; however, a significant proportion of patients develop serious treatment-related side effects or experience relapse. Recent advances in our understanding of the pathogenesis of AAV have led to the identification of novel therapeutic targets that may address these problems, including strategies directed at the aberrant adaptive autoimmune response (B and T cell-directed treatments) and those targeting innate immune elements (complement, monocytes, and neutrophils). It is anticipated that these novel treatments, used alone or in combination, will lead to more effective and less toxic treatment regimens for patients with AAV.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Prendecki M, McAdoo SP. New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021. PMID: 32562366. doi:10.1002/art.41407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。